Epigral Limited — Others, 05-06-2025: Shareholders meeting

Epigral Limited has announced a board meeting to consider the financial results for the quarter and half-year. The company reported record FY25 revenue of ₹2,565 Cr, up 33%, driven by volume growth in derivative and specialty chemicals. EBITDA rose 48% to ₹711 Cr, with net profit up 82% to ₹357 Cr, supported by better product mix and plant utilization. Capacity expansions at its Dahej facility and new facilities like the Chlorotoluenes value chain and an 18.34 MW wind-solar plant enhance cost efficiency and market leadership. Net debt-to-EBITDA improved to 0.7x, and credit ratings were upgraded to CRISIL AA/Stable. A total dividend of ₹6 per share is proposed.